Introduction
============

Lung cancer is one of the most common malignancies, and the leading cause of cancer-associated mortality worldwide. The mortality of lung cancer has decreased over the past decade, and the current 5-year survival rate is \~18%. These alterations are attributed to a decrease in tobacco use, the progress in lung cancer screening with low-dose computed tomography, and improvements in treatment in recent years ([@b1-ol-0-0-10016]). Novel targeted treatments for advanced non-small-cell lung cancer (NSCLC) based on driver mutations and immune checkpoints are continuously being developed ([@b2-ol-0-0-10016]--[@b4-ol-0-0-10016]). Epidermal growth factor receptor (EGFR) mutations are the most frequent driver mutations detected in lung adenocarcinomas and exhibit clinically therapeutic implications. The occurrence of these mutations varies between races, ranging from \~14% in Caucasian patients to almost 50% in Asian patients, particularly those with adenocarcinoma ([@b5-ol-0-0-10016],[@b6-ol-0-0-10016]). Currently, the detection of EGFR mutations relies mainly on tissue specimens, and the identification of a mutation-positive tissue is the premise of targeted therapy. Tests examining circulating tumor DNA (ctDNA) are also used in the clinic. An early report detected EGFR mutations in circulating tumor cells (CTCs) using a microfluidic device, and achieved high rates of detecting EGFR-activating mutation ([@b7-ol-0-0-10016]).

In the present study, a fast, simple CTC isolation technique was established based on the CellSearch^®^ principle ([@b8-ol-0-0-10016],[@b9-ol-0-0-10016]), which may simplify the verification of the EGFR status in CTCs. The status of EGFR mutations was evaluated by isolating blood epithelial cells from patients with advanced NSCLC prior to treatment with tyrosine kinase inhibitors (TKIs). The isolation and analysis of a few mixed CTCs significantly improved the detection rate of EGFR mutations compared with detection using single CTCs, and isolated CTCs were potentially useful for analyzing the heterogeneity of mutations.

Materials and methods
=====================

### Patients and ethics

The study was approved by the Beijing Chest Hospital Committee on the Use of Humans as Experimental Subjects (Beijing China). In addition, all participants provided written informed consent. Patients were diagnosed with biopsy-validated lung cancer in clinical phase III or IV. The 57 male and 34 female patients had an age range of 32 to 87 years and a mean age of 62.3 years. Blood samples (4.5 ml) were collected into Vacuette EDTA anticoagulant tubes (Greiner Bio-One GmbH, Kremsmünster, Austria) from 91 untreated patients with lung cancer at the Beijing Chest Hospital, and processed within 2 h using an autoMACS Pro instrument (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).

### CTC enrichment and single-cell retrieval

Erythrocyte lysates were prepared from blood samples using BD FACS Lysing Solution (BD Biosciences, San Jose, CA, USA). Following red blood cell depletion, the Fc receptor reagent (cat. no. 120-000-442; Miltenyi Biotec GmbH) and cluster of differentiation CD326 microbeads (cat. no. 130061101; Miltenyi Biotec GmbH) were used according to the manufacturer\'s protocol. The cell suspension was subsequently loaded onto an autoMACS Pro instrument, and CD326+ and CD326- fractions were obtained. The CD326+ cell fraction was stained with anti-epithelial cell adhesion molecule (EpCAM)-phycoerythrin (cat. no. 565399; BD Biosciences), three types of anti-cytokeratin-fluorescein isothiocyanate antibody (cat. no. ab870010, Abcam, Cambridge, UK; cat. no. ab72813, Abcam; cat. no. 53-9898, eBioscience; Thermo Fisher Scientific, Inc., Waltham, MA, USA), anti-CD45allophycocyanin antibodies (cat. no. ab28106; Abcam), and Hoechst 33342 (cat. no. C0030; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) to distinguish cancerous cells from healthy leukocytes. Individual CTCs (EpCAM+, Hoechst+, anti-cytokeratin+, anti-CD45-) were isolated from leukocytes (anti-CD45+, Hoechst+, anti-cytokeratin-, EpCAM-) using a fluorescence microscope (Nikon Corporation, Tokyo, Japan) with a robotic micromanipulator (CellEctor; Molecular Machines & Industries GmbH, Eching, Germany). A total of three commercially available lung cancer adenocarcinoma cell lines (NCI-H2009, NCI-H1975, and HCC-827) were purchased from The American Type Culture Collection (Manassas, VA, USA) for spiking experiments and mutation analyses. For spiking experiments, CTCs were picked up by applying CellEctor and spiked into 4.5 ml blood.

### DNA amplification

The selected CTCs were used for whole-genome amplification (WGA) and quantification using a REPLI-g^®^ Single Cell kit (cat. no. 150343; Qiagen GmbH, Hilden, Germany). The procedure was performed according to the manufacturer\'s protocol. DNA was quantified using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA), according to the manufacturer\'s protocol. The amplified DNA was verified by polymerase chain reaction (PCR) using the Multiplex PCR kit (cat no. 206143; Qiagen GmbH) and eight pairs of primers specific for housekeeping genes were designed. The primers used were follows: CYB5A forward, 5′-GGCAACGCTTAGACTCTGTGTG-3′ and reverse, 5′-CTGCCCTTGGCCTAACTAACCT-3′; PRPH forward, 5′-GTTCCTCAAGAAGCTGCACGAG-3′ and reverse, 5′-CGTTAGACTCTGGATCTGGCGT-3′; GABARAPL2 forward, 5′-CCAGCCAATTCATGAGTCGGTG-3′ and reverse, 5′-CCTGACAACTCGCAAGTAGCAC-3′; ACTG1 forward, 5′-GCTCAATGGGGTACTTCAGGGT-3′ and reverse, 5′-GTGGACGTTACGTAAAAGGCCC-3′; NDUFA7 forward, 5′-TGCTCTGGATGTGAAGATGCCA-3′ and reverse, 5′-TTCCAGGTAAATCCAGCCCAGG-3′; UQCRC1 forward, 5′-CAGCCAGTCAGCATCATCCAAC-3′ and reverse, 5′-GAAAGCCGGATTGCGGTAACAT-3′; MYC forward, 5′-GGATAGCTCTGCAAGGGGAGAG-3′ and reverse, 5′-TCGTCGCAGTAGAAATACGGCT-3′; and MIF forward, 5′-AGAAGTCAGGCACGTAGCTCAG-3′ and reverse, 5′-GGCACGTTGGTGTTTACGATGA-3′.

### Sequence and copy number variation (CNV) analyses

For the analysis of CNVs, DNA was quantitatively amplified from 2.5 ng/ml WGA products for library preparation and barcoded with a Nextera Index kit (Illumina, Inc., San Diego, CA, USA). The low-quality reads were removed from the obtained data using the Illumina procedure following data quality control, and Burrows-Wheeler Alignment Tool (version 0.7.15) ([@b10-ol-0-0-10016],[@b11-ol-0-0-10016]) was used to compare the sequences to the human genome (hg19). The data normalized by unique reads were considered CNVs. Our test samples used white blood cells from the same patient as a reference for comparison.

### EGFR mutation detection

EGFR mutations were detected using a quantitative fluorescence PCR instrument (Cobas z480; Roche Diagnostics, Basel, Switzerland) and an EGFR detection kit (human EGFR gene mutations fluorescence PCR diagnostic kit; Amoy Diagnostics Co., Ltd., Xiamen, China) according to the manufacturers\' protocols. EGFR mutations were also analyzed by digital PCR (dPCR; ABI-QuantStudio 3D, Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the protocols for the Dual Flat Block GeneAmp PCR System 9700 (Thermo Fisher Scientific, Inc.); dPCR primers and probes (cat no. A44177; Assay ID, HS000000026_rm; Thermo Fisher Scientific, Inc.) for EGFR mutation detection were purchased from Applied Biosystems. QuantStudio™ 3D AnalysisSuite™ software version 3.1.2 (Thermo Fisher Scientific, Inc.) was used for data acquisition and analysis.

### Statistical analyses

Counts were compared using the χ^2^ test. Continuous data were compared using Student\'s t-test if the distribution of samples was normal, or nonparametric tests (the Mann-Whitney U test) for comparisons between two groups. For each test, two-sided P\<0.05 was considered to indicate a statistically significant difference. All statistical manipulations were performed using the SPSS version 18 for Windows software system (SPSS, Inc., Chicago, IL, USA).

Results
=======

### A simplified technique to yield high-purity epithelial tumor cells from blood

An H2009 lung cancer cell line that stably expressed both EpCAM and cytokeratins (CKs) was selected for spiking experiments to establish an approach for isolating tumor cells from blood. The aim was to optimize the collection of pure CTCs for further molecular characterization at the individual cell level. An illustration of the CTC capture method is displayed in [Fig. 1A](#f1-ol-0-0-10016){ref-type="fig"} and includes the following steps: i) Ammonium chloride-based red blood cell lysis; ii) enrichment of disseminated cancer cells using magnetically coated anti-EpCAM beads; and iii) micromanipulation to obtain single cells. In the present study, two epithelium-specific staining procedures (using EpCAM and CK antibodies) were performed to identify cancer cells, including EpCAM bead enrichment followed by staining with a monoclonal antibody against EpCAM that bound well to the cancer cell surface ([Fig. 1B](#f1-ol-0-0-10016){ref-type="fig"}). The recovery rates of H2009 cells (≥1 cell) ranged from 62.5--83.8% in four independent experiments ([Fig. 1C and D](#f1-ol-0-0-10016){ref-type="fig"}) and increased when increasing the number of spiked cancer cells via the precise recovery of cells using micromanipulation. Similar capture efficiencies were achieved using cell lines exhibiting relatively low EpCAM expression levels, including the lung cancer cell lines H1975 and HCC-827. Using EpCAM and CK double staining, epithelial marker-positive cells were not detected in samples from 20 healthy subjects, from 10 patients with tuberculosis and from 10 patients with other nonmalignant lung diseases. This protocol was subsequently used to obtain rare CTCs from clinical samples.

### Efficient real-time isolation of CTCs from patients with advanced lung cancer

A total of 91 patients with advanced lung cancer were enrolled for the CTC analysis as described in this study, between March 2016 and October 2017. Patient characteristics were recorded, and ages ranged from 32--83 years; 63% were male and 66% had adenocarcinoma. Patients with TNM stage III and IV diseases represented 18 and 82% of the lung cancer cohort, respectively.

Among the total population, 56 patients (61.5%) exhibited positive CTC counts at baseline, with the detection of at least one CTC in 4.5 ml of peripheral blood (range, 1 to 29; median 2; mean 4.60). All identified cells were single CTCs, and no clusters were detected. Representative images of CTCs from individual patients are illustrated in [Fig. 2](#f2-ol-0-0-10016){ref-type="fig"}. The prevalence of CTCs prior to treatment and the association with patient characteristics are listed in [Table I](#tI-ol-0-0-10016){ref-type="table"}. i) Stage IV NSCLC was significantly associated with higher CTC numbers (Mann-Whitney test, P=0.0081). At least one CTC was detected in 52 (69.3%) of the 75 patients with stage IV disease. In addition, at least one CTC was detected in four (25.0%) of the 16 patients with stage III NSCLC ([Fig. 3](#f3-ol-0-0-10016){ref-type="fig"}), and CTCs were also detected in one of the four patients with stage IIIa NSCLC, in whom two CTCs were captured. Detectable CTCs, albeit at lower numbers, positively correlated with bone and brain metastases compared with metastatic disease at other sites. Among 56 patients with CTCs, patients with bone, brain, liver and kidney metastasis accounted for 31/56 (55.3%), 25/56 (44.6%), 15/56 (26.8%) and 9/56 (16.1%) of the patients, respectively. Furthermore, the number of CTCs detected was specifically associated with bone metastasis, and the mean number of CTCs detected in patients with bone metastases was 5.7. ii) According to the histological features, patients with small-cell lung cancer (SCLC) displayed the highest CTC counts and a CTC detection rate of 77.8% (7 of 9 patients; median, 5; mean, 8.22) compared with patients with NSCLC or other types of metastatic diseases (P\>0.05; [Fig. 3A](#f3-ol-0-0-10016){ref-type="fig"}). iii) No significant association was observed between a higher CTC number and tumor burden or smoking status; however, a clear trend toward a correlation between an increased CTC detection rate and increased tumor diameter was observed (\<3 cm, 48.7% vs. ≥3 cm, 71.1%; P=0.078).

### CNV analysis and single-cell EGFR mutation detection

The use of CTCs as a real-time liquid biopsy has attracted increasing attention. Accurate and reliable techniques for the capture of purified CTCs from peripheral blood are therefore required to facilitate the clinical utility of CTC analyses. WGA was performed for DNA amplification and to identify the genomic features of CTCs. The DNA was subsequently subjected to CNV analyses. Multiple chromosomal variations were observed in the H2009 lung cancer cell line at the single-cell level, compared with those in normal white blood cells. Representative CNV profiles of five patients are illustrated in [Fig. 4](#f4-ol-0-0-10016){ref-type="fig"}. Tumor-characteristic CNVs were detected in four patients using 1--10 CTCs. Based on the sensitivity of 1/1,000 copies for dPCR and 1/100 copies for the amplification refractory mutation system (ARMS) procedures, our study confirmed that both dPCR- and ARMS-based assays were suitable for analyzing mutations in single H1975 or HCC-827 cells, as displayed in [Fig. 5](#f5-ol-0-0-10016){ref-type="fig"}. A total of three other lung cancer cell lines were also used to verify that dPCR- and ARMS-based approaches were effective for the detection of expected EGFR mutations ([Table II](#tII-ol-0-0-10016){ref-type="table"}).

### Homogeneity analysis of CTC-EGFR mutations

Initially, EGFR mutations were analyzed in single CTCs following WAG; two single cells carried the same EGFR mutations as the primary tumor among 12 single cells derived from different patients using dPCR- and ARMS-based detection methods, indicating a 16.67% sensitivity. When samples containing more CTCs (10 CTCs from four patients) were analyzed, all the samples displayed clear EGFR mutation status, consistent with the tumor tissue, including two patients with the L858R mutation, one patient with the 19del mutation, and one patient with a non-activating mutation. The two samples with the L858R mutation were further confirmed by dPCR.

### Inconsistent rare EGFR mutations are identifiable in CTCs

In addition to the four patients described above, EGFR mutations were also detected in the remaining four samples, with CTC numbers ranging between three and nine cells. Among them, two samples yielded identical results to those of the tissue, while one sample contained four CTCs from the patient (patient 2) that were detected as wild type, which was a different result from the tissue pathological examination that revealed a 19del mutation. Another sample from patient 4 contained three CTCs in which a single new G791× mutation was detected that differed from the L858R mutation that was observed in this patient\'s tumor tissue ([Table III](#tIII-ol-0-0-10016){ref-type="table"}).

Discussion
==========

A number of promising techniques, including the use of microfluidic and microarray devices, may potentially enrich CTCs with greater sensitivity. However, these techniques have not been approved for clinical use, and their utility in the discovery of new CTC markers is in the early stages of development. The CellSearch^®^ system has undergone extensive development and is an accredited method for analyzing CTCs ([@b12-ol-0-0-10016],[@b13-ol-0-0-10016]). Current technical challenges include methods of increasing CTC purity and isolating single CTCs for molecular analysis. Researchers universally acknowledge that no single marker is able to reliably identify CTCs. Mainstream techniques continue to focus on utilizing common epithelial cell-specific markers, including EpCAM and CKs, which were introduced as a basic principle by the CellSearch^®^ system. A key issue in conducting the present study was isolating high-quality CTCs. Therefore, the aim was to isolate CTCs from blood cells based on epithelial cell-specific markers. The system would need to be simple and automated for widespread clinical use; however, manual CTC retrieval under the microscope was an essential step to ensure the capture of single or pure CTCs. The CTC isolation technique was tested using 4.5 ml of blood in spiking experiments and exhibited a recovery rate between 62.5--83.8%, more efficient than that of previous reports on CTC detection using 7.5 ml blood ([@b8-ol-0-0-10016]). This increase in capture efficiency may be attributed to double staining for EpCAM and CKs, as EpCAM is not expressed by all carcinomas, and as many as 30% express low levels of EpCAM. Moreover, the expression levels of CKs vary among different histological subtypes ([@b14-ol-0-0-10016],[@b15-ol-0-0-10016]). Simultaneous staining with multiple epithelial markers and confirmation of negative staining for leukocyte markers such as CD45, has become the standard for reliably identifying CTCs ([@b16-ol-0-0-10016]). Additionally, CTCs with low EpCAM expression have also been detected using a similar capture system ([@b17-ol-0-0-10016]). Among patients with lung cancer, the CTC count significantly increased in advanced tumor, such as SCLC and tumor progression, particularly with the development of distant metastasis. These findings are consistent with previous reports ([@b18-ol-0-0-10016],[@b19-ol-0-0-10016]).

The CellSearch^®^ system has indicates promise for reliable and reproducible CTC enumeration in the clinic, and it has been approved for the evaluation of lung cancer. Patients without clinically detectable distant metastases will likely exhibit low CTC detection rates ([@b8-ol-0-0-10016]). Therefore, 91 patients with stage III and IV diseases were enrolled to evaluate the efficacy of a CTC detection protocol. In general, the results were similar to previously reported findings; the CTC count significantly increased with tumor progression, with a detection rate of 69.3% among patients with advanced stage IV NSCLC ([@b18-ol-0-0-10016],[@b19-ol-0-0-10016]), and CTCs were most abundant in patients with SCLC, as CTCs were detected in 77.8% of patients with this type of cancer ([@b20-ol-0-0-10016]). A clear trend towards an increased CTC detection rate with increased tumor size was also observed, although the association between higher CTC numbers and greater tumor size was not statistically significant. A detailed analysis of additional samples may be required to verify the association between CTC numbers and the actual tumor burden, rather than primary tumor size (volume). In contrast to a microfluidic device-confirmed CTC cluster, no CTC clusters were isolated from the 91 patients using our established protocol; this result was consistent with those from other reports using the CellSearch^®^ system. It was concluded that in the present study, a simplified protocol using double staining resulted in a higher CTC capture rate and is suitable for clinical use, including single-cell detection. Moreover, previous studies have confirmed the prognostic significance of CTCs in patients with lung cancer, indicating that the CTC number is an independent prognostic factor for SCLC at baseline and following chemotherapy ([@b19-ol-0-0-10016],[@b20-ol-0-0-10016]).

Notably, ctDNA has been identified as a specific and sensitive biomarker for the detection of EGFR mutations ([@b21-ol-0-0-10016]--[@b23-ol-0-0-10016]). ctDNA is a part of the total circulating-free DNA, comprising small fragments of between 70 and 200 base pairs, and is released from dead cancer cells via apoptosis, necrosis and other mechanisms that remain to be clarified ([@b24-ol-0-0-10016]). The detection of ctDNA is also a characteristic of tumors with high cellular turnover. Cell-free ctDNA is frequently evaluated in non-invasive, early diagnostic screens to monitor responses and disease prognosis and to monitor resistance to treatment ([@b25-ol-0-0-10016]). In this regard, the biology of CTCs will hopefully be better understood with the availability of more comprehensive molecular characterization data, and information on their clinical implications ([@b26-ol-0-0-10016]).

In the clinic, decisions regarding therapy rely heavily on local tumor analyses. Biopsies of primary lesions are invasive procedures; therefore, an analysis of CTCs as representative surrogates for primary and metastatic lesions may be a potential alternative that may also enable the real-time assessment of resistance to therapy ([@b27-ol-0-0-10016]). Deep-sequencing genomic analyses of CTCs from primary tumors and metastases in patients with colorectal or prostate cancer have revealed that mutations in CTCs resemble those detected in primary tumors and metastases. These data have important implications for the use of CTCs as a liquid biopsy ([@b13-ol-0-0-10016],[@b27-ol-0-0-10016],[@b28-ol-0-0-10016]). Using a microfluidic device, the expected activating EGFR mutations identified in the original tumor biopsy specimens have also been detected in CTCs from 11 of 12 patients with lung cancer (92%) ([@b4-ol-0-0-10016]). More recently, a novel *in vivo* device was used to capture circulating lung cancer cells from one patient, and the same EGFR mutations identified in the primary tumors were clearly detectable in the collected CTCs ([@b29-ol-0-0-10016]). In the present study, detection of EGFR mutations at the single-cell level was initially attempted; however, this strategy was less effective, as only \~16% of cells were positive for mutations in the analysis of 12 single cells derived from different patients with a known primary mutation. A subsequent study revealed that a sample with 10 CTCs exhibited an increased detection rate and proved effective in detecting the mutation identified in the primary tumor. Another study reported a similar result of a low percentage of EGFR mutations in CTCs analyzed using next-generation sequencing ([@b30-ol-0-0-10016]). Based on these results, as little as one CTC is appropriate for detecting EGFR mutations, and when the CTC number is decreased, sensitivity decreases. Generally, EGFR mutations were homogeneous. However, we observed one notable exception, in which a clear rare mutation was detected that differed from the primary mutation.

Although the present study is limited by the small sample size, particularly for the EGFR mutation analysis, the preliminary results support an expanded study using isolated CTCs to detect EGFR mutations and a potent heterogeneity analysis of somatic copy number alterations and mutations.
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![Isolation of spiked cancer cells from peripheral blood based on epithelial markers. (A) Peripheral blood was enriched by depleting red and white blood cells using the autoMACS Pro instrument. The remaining cells were stained with a panel of fluorescent antibodies. CTCs were defined as CK+/EpCAM+/DAPI+/CD45- cells, and micromanipulation was performed under a fluorescence microscope. (B) Expression of EpCAM on the surface of spiked H2009 lung cancer cells. (C) Tabulated and (D) graphical representation of the recovery rates for four independent spiking experiments. EpCAM, epithelial cell adhesion molecule; CK, cytokeratin; CTC, circulating tumor cell; Exp, experiment; FITC, fluorescein isothiocyanate; CD; cluster of differentiation.](ol-17-04-3799-g00){#f1-ol-0-0-10016}

![Representative images of individual CTCs isolated from 4.5 ml of blood from patients with advanced lung cancer (magnification, ×400). CTCs 1--4 were captured from four different patients with lung cancer; CTCs 5--7 were captured from the same patient with lung cancer. Tumor cells were identified as EpCAM-positive (red-PE), pan-CK-positive (green-FITC), CD45-negative (gray-APC) and Hoechst 33342-positive (blue) cells. CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; CK, cytokeratin; PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, allophycocyanin; BF, bright field; CD, cluster of differentiation.](ol-17-04-3799-g01){#f2-ol-0-0-10016}

![Association of CTC counts among all patients based on tumor histology and staging. The mean number of detected CTCs is illustrated. (A) Patients with SCLC had the highest CTC counts and a CTC detection rate of 77.8% (7 of 9 patients; median 5; mean 8.22) compared with patients with NSCLC or other types of metastatic disease. (B) TNM Stage IV NSCLC was significantly associated with higher CTC numbers (Mann-Whitney test, P=0.0081). At least 1 CTC was detected in 52 (69.3%) of the 75 patients with TNM stage IV disease. At least 1 CTC was detected in four (25.0%) of the 16 patients with TNM stage III disease. CTC, circulating tumor cell; SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; Adeno, adenocarcinoma; TNM, tumor, node, metastasis.](ol-17-04-3799-g02){#f3-ol-0-0-10016}

![CNV analysis. Epithelial cell adhesion molecule+ and cytokeratin+ cells isolated from the peripheral blood of patients with lung cancer were used for whole-genome amplification followed by next-generation sequencing. Each panel represents 1--10 circulating tumor cells from different patients (patients 1--4) with confirmed CNVs, and CNVs in the H2009 lung cancer cell line were used as a positive reference. The CNV analysis was performed using the Cancer Gene Census database. CNV, copy number variation.](ol-17-04-3799-g03){#f4-ol-0-0-10016}

![Detection of common EGFR mutations by dPCR and ARMS at the single-cell level. EGFR mutations L858R and 19del were detected in the amplified genomic DNA from single cancer cells (NCI-H1975 and HCC-827) by (A) 3D dPCR and (B) ARMS, respectively. dPCR, digital polymerase chain reaction; ARMS, amplification refractory mutation system; EGFR, epidermal growth factor receptor; FAM, 5-carboxyfluorescein; VIC, 2′-chloro-7′ phenyl-1,4-dichloro-6-carboxy-fluorescein.](ol-17-04-3799-g04){#f5-ol-0-0-10016}

###### 

Correlation between captured CTC counts and clinical characteristics among patients with lung cancer prior to treatment.

                                       CTC count (%)                                                  
  ------------------------ ----------- --------------- ------------ ----------- ----------- --------- -----------
  All patients (n=91)      56 (61.5)   35 (38.5)       10 (10.99)   15 (16.5)   11 (12.1)   6 (6.6)   14 (15.4)
  C-stage                                                                                             
    III (n=16)             4 (25.0)    12 (75)         0 (0)        1 (6.3)     2 (12.4)    0 (0)     1 (6.3)
    IV (n=75)              52 (69.3)   23 (30.7)       10 (13.3)    14 (18.7)   9 (12)      6 (8)     13 (17.3)
  Histological cell type                                                                              
    Adeno (n=60)           36 (60.0)   24 (30)         7 (11.7)     12 (20)     5 (8.3)     5 (8.3)   7 (11.7)
    SCC (n=16)             10 (62.5)   6 (37.5)        2 (12.5)     2 (12.5)    2 (12.5)    1 (6.3)   3 (18.7)
    SCLC (n=9)             7 (77.8)    2 (22.2)        0 (0)        0 (0)       4 (44.4)    0 (0)     3 (33.3)
    Other (n=6)            3 (50.0)    3 (50)          1 (33.3)     1 (33.3)    0 (0)       0 (0)     1 (33.3)
  Smoking history                                                                                     
    Yes (n=61)             36 (59.0)   25 (41)         3 (4.9)      11 (18.0)   8 (13.1)    5 (8.2)   9 (14.8)
    No (n=30)              20 (66.7)   10 (33.3)       7 (23.3)     4 (13.3)    3 (10)      1 (3.3)   5 (16.7)
  Tumor size                                                                                          
    \<3 cm (n=39)          19 (48.7)   20 (51.3)       4 (10.3)     5 (12.8)    2 (2.2)     3 (5.1)   5 (12.8)
    \>3 cm (n=52)          37 (71.1)   15 (28.9)       6 (11.5)     10 (19.2)   9 (17.3)    3 (5.8)   9 (17.3)

CTC, circulating tumor cell; Adeno, adenocarcinoma; SCC, squamous cell carcinoma; and SCLC, small-cell lung cancer

###### 

Lung cancer cell lines with the expected EGFR mutations and the EGFR mutations detected by digital polymerase chain reaction or amplification refractory mutation system.

              EGFR mutation                
  ----------- --------------- ------------ -------
  NCI-H2009   Wild-type       Wild-type    Adeno
  HCC-827     19del           19del        Adeno
  NCI-H1975   L858RT790M      L858RT790M   Adeno

EGFR, epidermal growth factor receptor; Adeno, adenocarcinoma

###### 

Analysis of the consistency of EGFR mutations among various CTCs and tissue specimens.

               EGFR mutation (ARMS)           
  --- --- ---- ---------------------- ------- -----
  1   1   10   L858R                  L858R   Yes
      2   9    L858R                  L858R   Yes
  2   1   10   19del                  19del   Yes
      2   4    19del                  N       No
  3   1   10   N                      N       Yes
      2   3    N                      N       Yes
  4   1   10   L858R                  L858R   Yes
      2   3    L858R                  G719X   No

CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; ARMS, amplification refractory mutation system
